4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004 for Knee Osteoarthritis Treatment

4Moving Biotech, a spin-off of 4P-Pharma, has enrolled its first patient in the Phase 2a trial of 4P004, a potential first-in-class GLP-1 therapy for knee osteoarthritis. The multicenter, randomized, double-blind, placebo-controlled trial aims to evaluate the efficacy of 4P004 in 129 patients worldwide diagnosed with knee OA. The primary endpoint is the reduction in knee pain at week 4 and 12, with secondary objectives including assessing synovial changes and exploratory analysis of blood and imaging biomarkers. The study timeline covers 12 months, with a topline readout expected in the second half of 2026.

Title: 4Moving Biotech Enrolls First Patient in Phase 2a Trial for Knee Osteoarthritis Therapy

Lille, France & Paris, July 2, 2025 - 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments for knee osteoarthritis (OA), has announced the enrollment of its first patient in the Phase 2a clinical trial, INFLAM MOTION. The trial aims to evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee OA.

INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients diagnosed with knee OA will be enrolled to evaluate the efficacy of 4P004. The primary endpoint is the reduction in knee pain at weeks 4 and 12, with key secondary objectives including assessing synovial changes by contrast-enhanced MRI and conducting an exploratory analysis of blood and imaging biomarkers.

The study's timeline covers 12 months, with patient enrollment taking place over 9 months and follow-up to be completed before the topline readout in the second half of 2026. The trial is designed to generate the first human evidence that 4P004 can deliver both clinical relief and measurable structural benefit.

"Enrolling our first patient is a pivotal step toward rewriting the treatment paradigm for knee osteoarthritis," said Professor Francis Berenbaum, MD, PhD, Chief Medical Officer at 4Moving Biotech. "Almost 600 million people live with OA, yet no disease-modifying therapy has been done to patients. By acting directly in the joint, 4P004 tackles pain, inflammation, and tissue damage through GLP-1-mediated pathways. We believe its targeted intra-articular delivery can unlock the full therapeutic power of GLP-1 biology. We are eager to confirm both symptomatic relief and meaningful structural benefit in this proof-of-concept study."

4Moving Biotech, incorporated in mid-2020, is a clinical stage biotechnology company dedicated to developing the Disease-Modifying Osteoarthritis Drug (DMOAD). Its mission is to provide a sustainable therapeutic solution to the significant unmet medical need of osteoarthritis. The company is headquartered at the Pasteur Institute in Lille, France.

References:
[1] https://www.businesswire.com/news/home/20250715282394/en/4Moving-Biotech-Enrolls-First-Patient-in-Phase-2a-Trial-of-4P004-a-Potential-First-in-Class-GLP-1-Therapy-for-Knee-Osteoarthritis
[2] https://www.globenewswire.com/news-release/2025/07/15/3115546/0/en/PolyPid-Unveils-a-Long-Acting-GLP-1-Receptor-Agonists-Delivery-Platform-Targeting-the-Diabetes-and-Weight-Loss-Market.html